SPOTLIGHT: FDA: Expect more early warnings

The FDA is warning consumers to expect more communiques about drug side effects. As we noted last week, the number of "early communications" has increased recently, reflecting a new policy of alerting the public to possible problems earlier than in the past. The idea is to air info early, but make clear that any safety problems haven't yet been proven. Report

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.